Design, synthesis, and pharmacological characterization of novel endomorphin-1 analogues as extremely potent μ-opioid agonists

Journal of Medicinal Chemistry

Volumn 56, Issue 7, 2013, Pages 3102-3114

  Liu, Xin ^a   Wang, Yuan ^a   Xing, Yanhong ^a   Yu, Jing ^a   Ji, Hong ^a   Kai, Ming ^a   Wang, Zilong ^a   Wang, Dan ^a   Zhang, Yixin ^a   Zhao, Depeng ^a   Wang, Rui ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; ENDOMORPHIN 1; ENDORPHIN DERIVATIVE; FORSKOLIN; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST;

ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; TAIL FLICK TEST;

ANALGESICS; ANIMALS; CYCLIC AMP; DRUG DESIGN; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, MOLECULAR; OLIGOPEPTIDES; PHOSPHORYLATION; RECEPTORS, OPIOID, MU;

EID: 84876248490     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400195y     Document Type: Article

References (93)

1. Holden, J. E.; Jeong, Y.; Forrest, J. M. The endogenous opioid system and clinical pain management AACN Clin. Issues 2005, 16, 291-301
2. Janecka, A.; Fichna, J.; Janecki, T. Opioid receptors and their ligands Curr. Top. Med. Chem. 2004, 4, 1-17
3. Benyamin, R.; Trescot, A. M.; Datta, S.; Buenaventura, R.; Adlaka, R.; Sehgal, N.; Glaser, S. E.; Vallejo, R. Opioid complications and side effects Pain Physician 2008, 11, S105-120
4. Davis, M. P. Opioid receptor targeting ligands for pain management: a review and update Expert Opin. Drug Dis. 2010, 5, 1007-1022
5. Zadina, J. E.; Hackler, L.; Ge, L. J.; Kastin, A. J. A potent and selective endogenous agonist for the mu-opiate receptor Nature 1997, 386, 499-502
6. Hackler, L.; Zadina, J. E.; Ge, L. J.; Kastin, A. J. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex Peptides 1997, 18, 1635-1639
7. Vaccarino, A. L.; Kastin, A. J. Endogenous opiates: 2000 Peptides 2001, 22, 2257-2328
8. Wilson, A. M.; Soignier, R. D.; Zadina, J. E.; Kastin, A. J.; Nores, W. L.; Olson, R. D.; Olson, G. A. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats Peptides 2000, 21, 1871-1874
9. Czapla, M. A.; Gozal, D.; Alea, O. A.; Beckerman, R. C.; Zadina, J. E. Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine Am. J. Respir. Crit. Care Med. 2000, 162, 994-999
10. Liu, W. X.; Wang, R. Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs Med. Res. Rev. 2012, 32, 536-580
11. Keresztes, A.; Borics, A.; Toth, G. Recent advances in endomorphin engineering ChemMedChem 2010, 5, 1176-1196
12. Tomboly, C.; Peter, A.; Toth, G. In vitro quantitative study of the degradation of endomorphins Peptides 2002, 23, 1573-1580
13. Mentlein, R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides Regul. Pept. 1999, 85, 9-24
14. Shane, R.; Wilk, S.; Bodnar, R. J. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV Brain Res. 1999, 815, 278-286
15. Janecka, A.; Staniszewska, R.; Gach, K.; Fichna, J. Enzymatic degradation of endomorphins Peptides 2008, 29, 2066-2073
16. Cardillo, G.; Gentilucci, L.; Tolomelli, A. Unusual amino acids: synthesis and introduction into naturally occurring peptides and biologically active analogues Mini-Rev. Med. Chem. 2006, 6, 293-304
17. Schwyzer, R. ACTH: a short introductory review Ann. N.Y. Acad. Sci. 1977, 297, 3-26
18. 1H NMR spectroscopy and molecular modeling calculation J. Pept. Res. 2001, 58, 399-412
19. Berezowska, I.; Chung, N. N.; Lemieux, C.; Wilkes, B. C.; Schiller, P. W. Agonist vs antagonist behavior of δ opioid peptides containing novel phenylalanine analogues in place of Tyr(1) J. Med. Chem. 2009, 52, 6941-6945
20. Tomboly, C.; Ballet, S.; Feytens, D.; Kover, K. E.; Borics, A.; Lovas, S.; Al-Khrasani, M.; Furst, Z.; Toth, G.; Benyhe, S.; Tourwe, D. Endomorphin-2 with a β-turn backbone constraint retains the potent μ-opioid receptor agonist properties J. Med. Chem. 2008, 51, 173-177
21. Janecka, A.; Kruszynski, R. Conformationally restricted peptides as tools in opioid receptor studies Curr. Med. Chem. 2005, 12, 471-481
22. Janecka, A.; Staniszewska, R.; Fichna, J. Endomorphin analogs Curr. Med. Chem. 2007, 14, 3201-3208
23. Schiller, P. W. Bi- or multifunctional opioid peptide drugs Life Sci. 2010, 86, 598-603
24. Gentilucci, L.; Tolomelli, A. Recent advances in the investigation of the bioactive conformation of peptides active at the mu-opioid receptor. conformational analysis of endomorphins Curr. Top. Med. Chem. 2004, 4, 105-121
25. Hruby, V. J.; Balse, P. M. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads Curr. Med. Chem. 2000, 7, 945-970
26. Hruby, V. J.; Porreca, F.; Yamamura, H. I.; Tollin, G.; Agnes, R. S.; Lee, Y. S.; Cai, M.; Alves, I.; Cowell, S.; Varga, E.; Davis, P.; Salamon, Z.; Roeske, W.; Vanderah, T.; Lai, J. New paradigms and tools in drug design for pain and addiction AAPS J. 2006, 8, E450-460
27. Torino, D.; Mollica, A.; Pinnen, F.; Feliciani, F.; Lucente, G.; Fabrizi, G.; Portalone, G.; Davis, P.; Lai, J.; Ma, S. W.; Porreca, F.; Hruby, V. J. Synthesis and evaluation of new endomorphin-2 analogues containing (Z)-α,β-didehydrophenylalanine (δ(Z)Phe) residues J. Med. Chem. 2010, 53, 4550-4554
28. Giordano, C.; Sansone, A.; Masi, A.; Lucente, G.; Punzi, P.; Mollica, A.; Pinnen, F.; Feliciani, F.; Cacciatore, I.; Davis, P.; Lai, J.; Ma, S. W.; Porreca, F.; Hruby, V. Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2 Eur. J. Med. Chem. 2010, 45, 4594-4600
29. Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. Dmt and opioid peptides: a potent alliance Biopolymers 2003, 71, 86-102
30. Schiller, P. W. Opioid peptide-derived analgesics AAPS J. 2005, 7, E560-565
31. Seebach, D.; Overhand, M.; Kühnle, F.; Martinoni, B.; Oberer, L.; Hommel, U.; Widmer, H. β -Peptides: Synthesis by Arndt-Eistert homologation with concomitant peptide coupling. Structure determination by NMR and CD spectroscopy and by X-ray crystallography. Helical secondary structure of a β -hexapeptide in solution and its stability towards pepsin Helv. Chim. Acta 1996, 79, 913-941
32. Appella, D. H.; Christianson, L. A.; Karle, I. L.; Powell, D. R.; Gellman, S. H. β -Peptide foldamers: Robust helix formation in a new family of β -amino acid oligomers J. Am. Chem. Soc. 1996, 118, 13071-13072
33. Steer, D. L.; Lew, R. A.; Perlmutter, P.; Smith, A. I.; Aguilar, M. I. Beta-amino acids: versatile peptidomimetics Curr. Med. Chem. 2002, 9, 811-822
34. Keresztes, A.; Szucs, M.; Borics, A.; Kover, K. E.; Forro, E.; Fulop, F.; Tomboly, C.; Peter, A.; Pahi, A.; Fabian, G.; Muranyi, M.; Toth, G. New endomorphin analogues containing alicyclic β-amino acids: influence on bioactive conformation and pharmacological profile J. Med. Chem. 2008, 51, 4270-4279
35. Perlikowska, R.; Gach, K.; Fichna, J.; Toth, G.; Walkowiak, B.; do-Rego, J. C.; Janecka, A. Biological activity of endomorphin and [Dmt1]endomorphin analogs with six-membered proline surrogates in position 2 Bioorg. Med. Chem. 2009, 17, 3789-3794
36. Staniszewska, R.; Fichna, J.; Gach, K.; Toth, G.; Poels, J.; Vanden Broeck, J.; Janecka, A. Synthesis and biological activity of endomorphin-2 analogs incorporating piperidine-2-, 3- or 4-carboxylic acids instead of proline in position 2 Chem. Biol. Drug. Des. 2008, 72, 91-94
37. Torino, D.; Mollica, A.; Pinnen, F.; Lucente, G.; Feliciani, F.; Davis, P.; Lai, J.; Ma, S. W.; Porreca, F.; Hruby, V. J. Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue Bioorg. Med. Chem. Lett. 2009, 19, 4115-4118
38. Frackenpohl, J.; Arvidsson, P. I.; Schreiber, J. V.; Seebach, D. The outstanding biological stability of beta- and gamma-peptides toward proteolytic enzymes: an in vitro investigation with fifteen peptidases ChemBioChem 2001, 2, 445-455
39. Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. β-Peptides: From structure to function Chem. Rev. 2001, 101, 3219-3232
40. Spampinato, S.; Qasem, A. R.; Calienni, M.; Murari, G.; Gentilucci, L.; Tolomelli, A.; Cardillo, G. Antinociception by a peripherally administered novel endomorphin-1 analogue containing beta-proline Eur. J. Pharmacol. 2003, 469, 89-95
41. Wang, Y.; Xing, Y.; Liu, X.; Ji, H.; Kai, M.; Chen, Z.; Yu, J.; Zhao, D.; Ren, H.; Wang, R. A new class of highly potent and selective endomorphin-1 analogues containing α-methylene-β-aminopropanoic acids (map) J. Med. Chem. 2012, 55, 6224-6236
42. Zhao, D. P.; Yang, D. X.; Wang, Y. J.; Wang, Y.; Mao, L. J.; Wang, R. Enantioselective Mannich reaction of a highly reactive Horner-Wadsworth-Emmons reagent with imines catalyzed by a bifunctional thiourea Chem. Sci. 2011, 2, 1918-1921
43. Li, T.; Fujita, Y.; Tsuda, Y.; Miyazaki, A.; Ambo, A.; Sasaki, Y.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H.; Okada, Y. Development of potent μ-opioid receptor ligands using unique tyrosine analogues of endomorphin-2 J. Med. Chem. 2005, 48, 586-592
44. Liu, H. M.; Liu, X. F.; Yao, J. L.; Wang, C. L.; Yu, Y.; Wang, R. Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1 J. Pharmacol. Exp. Ther. 2006, 319, 308-316
45. Sasaki, Y.; Sasaki, A.; Niizuma, H.; Goto, H.; Ambo, A. Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high mu-opioid receptor affinity and selectivity Bioorg. Med. Chem. 2003, 11, 675-678
46. Koda, Y.; Del Borgo, M.; Wessling, S. T.; Lazarus, L. H.; Okada, Y.; Toth, I.; Blanchfield, J. T. Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides Bioorg. Med. Chem. 2008, 16, 6286-6296
47. Yabaluri, N.; Medzihradsky, F. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling Mol. Pharmacol. 1997, 52, 896-902
48. Liu, J. G.; Prather, P. L. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors J. Pharmacol. Exp. Ther. 2002, 302, 1070-1079
49. Hosohata, K.; Burkey, T. H.; Alfaro-Lopez, J.; Varga, E.; Hruby, V. J.; Roeske, W. R.; Yamamura, H. I. Endomorphin-1 and endomorphin-2 are partial agonists at the human mu-opioid receptor Eur. J. Pharmacol. 1998, 346, 111-114
50. 35S]GTPγS binding in rat brain: evidence for partial agonist activity at μ-opioid receptors J. Neurochem. 1998, 70, 1567-1576
51. Morou, E.; Georgoussi, Z. Expression of the third intracellular loop of the delta-opioid receptor inhibits signaling by opioid receptors and other G protein-coupled receptors J. Pharmacol. Exp. Ther. 2005, 315, 1368-1379
52. Belcheva, M. M.; Szucs, M.; Wang, D.; Sadee, W.; Coscia, C. J. μ-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation J. Biol. Chem. 2001, 276, 33847-33853
53. Fichna, J.; Perlikowska, R.; Wyrebska, A.; Gach, K.; Piekielna, J.; do-Rego, J. C.; Toth, G.; Kluczyk, A.; Janecki, T.; Janecka, A. Effect of 2′,6′-dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs Bioorg. Med. Chem. 2011, 19, 6977-6981
54. Asensio, V. J.; Miralles, A.; Garcia-Sevilla, J. A. Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal Eur. J. Pharmacol. 2006, 539, 49-56
55. Ferrer-Alcon, M.; Garcia-Fuster, M. J.; La Harpe, R.; Garcia-Sevilla, J. A. Long-term regulation of signalling components of adenylyl cyclase and mitogen-activated protein kinase in the pre-frontal cortex of human opiate addicts J. Neurochem. 2004, 90, 220-230
56. Cardillo, G.; Gentilucci, L.; Melchiorre, P.; Spampinato, S. Synthesis and binding activity of endomorphin-1 analogues containing beta-amino acids Bioorg. Med. Chem. Lett. 2000, 10, 2755-2758
57. Cardillo, G.; Gentilucci, L.; Qasem, A. R.; Sgarzi, F.; Spampinato, S. Endomorphin-1 analogues containing β-proline are μ-opioid receptor agonists and display enhanced enzymatic hydrolysis resistance J. Med. Chem. 2002, 45, 2571-2578
58. Mallareddy, J. R.; Borics, A.; Keresztes, A.; Kover, K. E.; Tourwe, D.; Toth, G. Design, synthesis, pharmacological evaluation, and structure-activity study of novel endomorphin analogues with multiple structural modifications J. Med. Chem. 2011, 54, 1462-1472
59. Guillemyn, K.; Kleczkowska, P.; Novoa, A.; Vandormael, B.; Van den Eynde, I.; Kosson, P.; Asim, M. F.; Schiller, P. W.; Spetea, M.; Lipkowski, A. W.; Tourwe, D.; Ballet, S. In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera Mol. Brain 2012, 5, 4
60. Befort, K.; Tabbara, L.; Bausch, S.; Chavkin, C.; Evans, C.; Kieffer, B. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site Mol. Pharmacol. 1996, 49, 216-223
61. 3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor J. Biol. Chem. 1996, 271, 21422-21429
62. Li, J. G.; Chen, C.; Yin, J.; Rice, K.; Zhang, Y.; Matecka, D.; de Riel, J. K.; DesJarlais, R. L.; Liu-Chen, L. Y. ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone Life Sci. 1999, 65, 175-185
63. Mansour, A.; Taylor, L. P.; Fine, J. L.; Thompson, R. C.; Hoversten, M. T.; Mosberg, H. I.; Watson, S. J.; Akil, H. Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study J. Neurochem. 1997, 68, 344-353
64. Mosberg, H. I.; Fowler, C. B. Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity J. Pept. Res. 2002, 60, 329-335
65. Surratt, C. K.; Johnson, P. S.; Moriwaki, A.; Seidleck, B. K.; Blaschak, C. J.; Wang, J. B.; Uhl, G. R. μ opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity J. Biol. Chem. 1994, 269, 20548-20553
66. Shahrestanifar, M.; Wang, W. W.; Howells, R. D. Studies on inhibition of mu and delta opioid receptor binding by dithiothreitol and N-ethylmaleimide. His223 is critical for mu opioid receptor binding and inactivation by N-ethylmaleimide J. Biol. Chem. 1996, 271, 5505-5512
67. Megaritis, G.; Merkouris, M.; Georgoussi, Z. Functional domains of delta- and mu-opioid receptors responsible for adenylyl cyclase inhibition Recept. Channels 2000, 7, 199-212
68. Mitch, C. H.; Quimby, S. J.; Diaz, N.; Pedregal, C.; de la Torre, M. G.; Jimenez, A.; Shi, Q.; Canada, E. J.; Kahl, S. D.; Statnick, M. A.; McKinzie, D. L.; Benesh, D. R.; Rash, K. S.; Barth, V. N. Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: Application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer J. Med. Chem. 2011, 54, 8000-8012
69. Pinyot, A.; Nikolovski, Z.; Bosch, J.; Segura, J.; Gutierrez-Gallego, R. On the use of cells or membranes for receptor binding: growth hormone secretagogues Anal. Biochem. 2010, 399, 174-181
70. Frandsen, E. K.; Krishna, G. A simple ultrasensitive method for the assay of cyclic AMP and cyclic GMP in tissues Life Sci. 1976, 18, 529-541
71. Obermeier, H.; Wehmeyer, A.; Schulz, R. Expression of mu-, delta- and kappa-opioid receptors in baculovirus-infected insect cells Eur. J. Pharmacol. 1996, 318, 161-166
72. Wei, Q.; Zhou, D. H.; Shen, Q. X.; Chen, J.; Chen, L. W.; Wang, T. L.; Pei, G.; Chi, Z. Q. Human mu-opioid receptor overexpressed in Sf9 insect cells functionally coupled to endogenous Gi/o proteins Cell Res. 2000, 10, 93-102
73. Gusovsky, F. Measurement of second messengers in signal transduction: cAMP and inositol phosphates. Current Protocols in Neuroscience; Wiley: New York, 2001, Chapter 7, Unit 7.12.
74. Korzh, A.; Keren, O.; Gafni, M.; Bar-Josef, H.; Sarne, Y. Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell Brain Res. 2008, 1189, 23-32
75. Belcheva, M. M.; Clark, A. L.; Haas, P. D.; Serna, J. S.; Hahn, J. W.; Kiss, A.; Coscia, C. J. Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes J. Biol. Chem. 2005, 280, 27662-27669
76. Schmidt, H.; Schulz, S.; Klutzny, M.; Koch, T.; Handel, M.; Hollt, V. Involvement of mitogen-activated protein kinase in agonist-induced phosphorylation of the mu-opioid receptor in HEK 293 cells J. Neurochem. 2000, 74, 414-422
77. Yu, Y.; Shao, X.; Cui, Y.; Liu, H. M.; Wang, C. L.; Fan, Y. Z.; Liu, J.; Dong, S. L.; Cui, Y. X.; Wang, R. Structure-activity study on the spatial arrangement of the third aromatic ring of endomorphins 1 and 2 using an atypical constrained C terminus ChemMedChem 2007, 2, 309-317
78. Rang, H. P. Stimulant actions of volatile anaesthetics on smooth muscle Br. J. Pharmacol. Chemother. 1964, 22, 356-365
79. Hughes, J.; Kosterlitz, H. W.; Leslie, F. M. Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics Br. J. Pharmacol. 1975, 53, 371-381
80. Gillespie, T. J.; Konings, P. N.; Merrill, B. J.; Davis, T. P. A specific enzyme assay for aminopeptidase M in rat brain Life Sci. 1992, 51, 2097-2106
81. Wang, C. L.; Yao, J. L.; Yu, Y.; Shao, X.; Cui, Y.; Liu, H. M.; Lai, L. H.; Wang, R. Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling Bioorg. Med. Chem. 2008, 16, 6415-6422
82. Liu, X.; Kai, M.; Jin, L.; Wang, R. Computational study of the heterodimerization between mu and delta receptors J. Comput.-Aided Mol. Des. 2009, 23, 321-332
83. Berendsen, H. J.; Vanderspoel, D.; Vandrunen, R. GROMACS: A message-passing parallel molecular dynamics implementation Comput. Phys. Commun. 1995, 91, 43-56
84. Vanbuuren, A. R.; Marrink, S. J.; Berendsen, H. J. C. A molecular dynamics study of the decane/water interface J. Phys. Chem. 1993, 97, 9206-9212
85. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N -log(N) method for Ewald sums in large system J. Chem. Phys. 1993, 98, 10089-10092
86. Hess, B.; Bekker, H.; Berendsen, H. J. C.; Fraaije, J. LINCS: A linear constraint solver for molecular simulations J. Comput. Chem. 1997, 18, 1463-1472
87. Berendsen, H. J. C.; Postma, J. P. M.; Vangunsteren, W. F.; Dinola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath J. Chem. Phys. 1984, 81, 3684-3690
88. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662
89. Hetenyi, C.; van der Spoel, D. Efficient docking of peptides to proteins without prior knowledge of the binding site Protein Sci. 2002, 11, 1729-1737
90. Hetenyi, C.; van der Spoel, D. Blind docking of drug-sized compounds to proteins with up to a thousand residues FEBS Lett. 2006, 580, 1447-1450
91. Hetenyi, C.; Paragi, G.; Maran, U.; Timar, Z.; Karelson, M.; Penke, B. Combination of a modified scoring function with two-dimensional descriptors for calculation of binding affinities of bulky, flexible ligands to proteins J. Am. Chem. Soc. 2006, 128, 1233-1239
92. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363
93. DeLano, W. L. The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA, 2002.